Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Humacyte, Inc.HUMA · Entity 6478 | Director | September 14, 2026 | September 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Humacyte, Inc.
Report date September 14, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 50,000 |
Reported balance
After 2026-09-14 transaction · row 1
1 source rowRow 1 · 2026-09-14 · Purchase · Acquired 10,000 · Balance 50,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 14, 2026 Filed Sep 15, 2026 20:05 UTC | Humacyte, Inc. HUMA · Entity 6478 | PurchaseCommon Stock | 10,000 | $0.56 | $5,620.00 |
DisclosureSEC source: 0001193125-26-391889 · ownership.xml · nonDerivative · entry 1 Jones Keith Anthony · CIK 0002026411 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 20:05 UTC | Humacyte, Inc. HUMA · Entity 6478 | PurchaseCommon Stock | 10,000 | $0.69 | $6,930.00 |
DisclosureSEC source: 0001193125-26-361081 · ownership.xml · nonDerivative · entry 1 Jones Keith Anthony · CIK 0002026411 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:00 UTC | Humacyte, Inc. HUMA · Entity 6478 | PurchaseCommon Stock | 30,000 | $0.59 | $17,820.00 |
DisclosureSEC source: 0001193125-26-356847 · ownership.xml · nonDerivative · entry 1 Jones Keith Anthony · CIK 0002026411 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 F1 · price: The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.590 to $0.596. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 11, 2026 Filed Jun 12, 2026 21:55 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 80,000 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001104659-26-073613 · tm2617880-6_4seq1.xml · derivative · entry 1 Jones Keith Anthony · CIK 0002026411 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2036-06-11 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:32 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 80,000 | $0.00 Strike: $2.41 | $0.00 |
DisclosureSEC source: 0001818382-25-000116 · wk-form4_1750105933.xml · derivative · entry 1 Jones Keith Anthony · CIK 0002026411 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2035-06-12 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 12, 2026, after which 1/48 of the option will become exercisable on the 12th of each month through June 12, 2029. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:11 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 75,000 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001818382-24-000137 · wk-form4_1718655110.xml · derivative · entry 1 Jones Keith Anthony · CIK 0002026411 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2034-06-13 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 13, 2025, after which 1/48 of the option will become exercisable on the 13th of each month through June 13, 2028. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.